

ONLINE SUPPLEMENTARY MATERIAL

Supplementary Table 1. Demographics, clinical characteristics, and treatment profiles of patients with PsA and without fibromyalgia in the Corrona PsA/SpA Registry at their enrollment visit, stratified by location of SPARCC enthesitis sites.

Characteristic	Patients Without Enthesitis (n = 1557)	Patients With Enthesitis			
		All Patients With Enthesitis (n = 349)	Upper Sites Only (n = 71)	Lower Sites Only (n = 120)	Both Upper and Lower Sites (n = 158)
Age, mean (SD), years	53.8 (13.3))	52.6 (12.8)	51.9 (12.8)	50.4 (12.5)*	54.6 (12.7)
Female, n (%)	745 (48.4)	209 (60.2)*	35 (49.3)	64 (53.8)	110 (70.1)*
White, n (%)	1418 (94.5)	320 (93.6)	66 (97.1)	110 (92.4)	144 (92.9)
BMI, mean (SD), kg/m ²	31.5 (7.3)	31.4 (7.0)	29.9 (5.9)	31.1 (6.1)	32.4 (7.8)
Marital status, n (%)					
Single	238 (15.5)	43 (12.5)	10 (14.5)	16 (13.4) [†]	17 (10.9)
Married	1055 (68.6)	239 (69.5)	45 (65.2)	82 (68.9) [†]	112 (71.8)
Partnered	18 (1.2)	9 (2.6)	1 (1.4)	5 (4.2) [†]	3 (1.9)
Widowed	72 (4.7)	10 (2.9)	2 (2.9)	1 (0.8) [†]	7 (4.5)
Separated	16 (1.0)	2 (0.6)	11 (15.9)	1 (0.8) [†]	1 (0.6)
Divorced	140 (9.1)	41 (11.9)	0	14 (11.8) [†]	16 (10.3)
Patient-reported work status, n (%)					
Full time	854 (55.6)	198 (57.2)	44 (63.8)	75 (62.5) [†]	79 (50.3)
Part time	130 (8.5)	31 (9.0)	7 (10.1)	10 (8.3) [†]	14 (8.9)

Disabled	120 (7.8)	33 (9.5)	1 (1.4)	13 (10.8) [†]	19 (12.1)
Retired	334 (21.7)	61 (17.6)	12 (17.4)	15 (12.5) [†]	34 (21.7)
Other	98 (6.4)	23 (6.6)	5 (7.2)	7 (5.8) [†]	11 (7.0)
Symptom duration, mean (SD), years	11.4 (10.4)	10.8 (10.0)	10.5 (9.6)	9.8 (9.6)	11.8 (10.5)
Disease duration, mean (SD), years	8.7 (9.0)	7.0 (8.0)*	6.8 (7.7)	6.4 (7.8)*	7.6 (8.4)
Physician-reported history of comorbid conditions, n (%)					
Psoriasis	1358 (87.2)	319 (91.4)*	66 (93.0)	110 (91.7)	143 (90.5)
Cardiovascular disease	769 (49.4)	172 (49.3)	36 (50.7)	53 (44.2)	83 (52.5)
Hypertension	562 (36.1)	126 (36.1)	23 (32.4)	41 (34.2)	62 (39.2)
Nail psoriasis	430 (27.6)	153 (43.8)*	38 (53.5)*	36 (30.0)	79 (50.0)*
Hyperlipidemia	374 (24.0)	79 (22.6)	17 (23.9)	24 (20.0)	38 (24.1)
Depression	175 (11.2)	56 (16.0)	7 (9.9)	25 (20.8)*	24 (15.2)
History of biologic use, n (%)	384 (24.7)	124 (35.5)*	21 (29.6)	43 (35.8)*	60 (38.0)*
No. of prior biologics, n (%)					
0	1173 (75.3)	225 (64.5) [†]	50 (70.4) [†]	77 (64.2) [†]	98 (62.0) [†]
1	259 (16.6)	81 (23.2) [†]	19 (26.8) [†]	26 (21.7) [†]	36 (22.8) [†]
≥ 2	125 (8.0)	43 (12.3) [†]	2 (2.8) [†]	17 (14.2) [†]	24 (15.2) [†]
History of csDMARD use, n (%)	350 (22.5)	113 (32.4)	23 (32.4)	40 (33.3)*	50 (31.6)*
History of tsDMARD use, n (%)	22 (1.4)	12 (3.4)*	2 (2.8)	4 (3.3)	6 (3.8)
Current csDMARD use only (no biologics or tsDMARDs), n (%)	428 (27.5)	77 (22.1)	18 (25.4)	20 (16.7)*	39 (24.7)

* $p < 0.05$ for comparison between the overall or location enthesitis groups and the no enthesitis group. † $p < 0.05$ for comparison of overall distribution across categories between the overall or location enthesitis groups and the no enthesitis group. BMI: body mass index; csDMARD: conventional synthetic disease-modifying antirheumatic drug; SPARCC: Spondyloarthritis Research Consortium of Canada; tsDMARD: targeted synthetic disease-modifying antirheumatic drug.

Supplementary Table 2. Disease activity, QOL, and work productivity of patients with PsA and without fibromyalgia in the Corrona PsA/SpA Registry at their enrollment visit, stratified by location of SPARCC enthesitis sites.

Characteristic*	Patients Without Enthesitis (n = 1557)	Patients With Enthesitis			
		All Patients With Enthesitis (n = 349)	Upper Sites Only (n = 71)	Lower Sites Only (n = 120)	Both Upper and Lower Sites (n = 158)
Modified MDA, n (%)	407 (31.7)	27 (9.0)	6 (9.8) [†]	13 (12.5) [†]	8 (5.9) [†]
Tender joint count (0-68)	2.7 (5.4)	11.7 (12.2)	8.4 (9.2) [†]	7.1 (9.3) [†]	16.5 (13.4) [†]
Swollen joint count (0-66)	1.8 (3.5)	3.7 (6.0)	3.7 (6.1) [†]	3.9 (7.0) [†]	3.6 (5.0) [†]
SPARCC Enthesitis Index (1-16)	0	3.9 (3.0)	2.1 (1.1)	2.1 (1.4)	6.2 (3.0) [†]
Dactylitis, n (%)	128 (8.2)	50 (14.3)	9 (12.7)	22 (18.3) [†]	19 (12.0)
Dactylitis count (1-20)	2.2 (1.7)	2.5 (1.9)	2.3 (1.4)	3.1 (2.5)	1.8 (1.0)
CDAI	10.8 (7.6)	16.8 (11.3)	14.4 (10.0) [†]	16.2 (12.3) [†]	18.4 (10.8) [†]
BSA, % affected	5.7 (11.5)	6.0 (12.2)	5.3 (8.8)	5.7 (12.6)	6.5 (13.1)
DAPSA	14.9 (13.1)	28.4 (18.8)	26.8 (19.0) [†]	22.8 (16.2) [†]	34.2 (19.5) [†]
cDAPSA	12.0 (10.2)	25.4 (18.3)	21.7 (16.7) [†]	21.0 (17.1) [†]	30.5 (18.7) [†]
Physician global assessment (VAS 0-100)	16.0 (18.4)	28.2 (21.2)	22.3 (18.9) [†]	29.0 (22.8) [†]	30.3 (20.5) [†]
Patient-reported pain (VAS 0-100)	35.0 (29.1)	49.8 (27.2)	42.8 (27.2) [†]	50.7 (28.7) [†]	52.3 (25.7) [†]
Patient-reported fatigue (VAS 0-100)	37.4 (29.1)	49.4 (27.6)	43.8 (28.6) [†]	48.0 (29.2) [†]	52.9 (25.5) [†]

Patient global assessment (VAS 0-100)	37.4 (29.1)	48.5 (27.7)	50.1 (30.0) [†]	46.6 (26.3) [†]	49.2 (27.7) [†]
HAQ-DI (0-3)	0.6 (0.6)	0.9 (0.6)	0.7 (0.6) [†]	0.8 (0.7) [†]	1.0 (0.6) [†]
EQ-5D (0-1)	0.8 (0.2)	0.7 (0.2)	0.8 (0.2) [†]	0.7 (0.2) [†]	0.7 (0.2) [†]
EQ-VAS (0-100)	73.6 (20.7)	65.6 (21.1)	70.0 (20.8) [†]	65.8 (21.5) [†]	63.6 (20.8) [†]
WPAI questionnaire domains					
Current employment, n (%)	939 (62.9)	210 (64.6)	46 (71.9)	82 (68.9)	82 (57.7)
% Work time missed	3.8 (14.3)	5.4 (14.0)	2.5 (8.3)	5.0 (15.0) [†]	7.5 (15.3) [†]
% Impairment while working	16.1 (21.4)	25.3 (23.9)	21.9 (24.5)	25.0 (24.2) [†]	27.6 (23.3) [†]
% Overall work impairment	17.7 (23.1)	28.5 (26.0)	23.6 (26.1)	28.2 (25.1) [†]	32.0 (27.0) [†]
% Activity impairment	24.4 (27.3)	39.9 (29.5)	30.3 (28.9)	40.8 (29.3) [†]	43.4 (29.4) [†]

* All values are presented as mean (SD) unless otherwise stated. [†] p < 0.05 for comparison

between the overall or body location between the enthesitis groups and the no enthesitis group.

BSA: body surface area; CDAl: Clinical Disease Activity Index; cDAPSA: clinical Disease

Activity Index for Psoriatic Arthritis; DAPSA: Disease Activity Index for Psoriatic Arthritis; EQ-5D:

Euroqol 5-dimension scale; EQ-VAS: Euroqol Quality of Life visual analog scale; HAQ-DI:

Health Assessment Questionnaire Disability Index; MDA: modified minimal disease activity

(defined as meeting ≥ 5 of the following criteria: tender joint count ≤ 1 , swollen joint count ≤ 1 ,

BSA $\leq 3\%$, patient pain VAS ≤ 15 , patient global assessment VAS ≤ 20 , and HAQ-DI ≤ 0.5);

PsA: psoriatic arthritis; QOL: quality of life; SpA: spondyloarthritis; SPARCC: Spondyloarthritis

Research Consortium of Canada; VAS: visual analog scale; WPAI: Work Productivity and

Activity Impairment.

Supplementary Table 3. Spearman correlation coefficients of SPARCC score with disease activity, QOL, and WPAI measures among patients with PsA and without fibromyalgia.

Variables	N	Spearman Correlation Coefficient	p Values
CDAI	1762	0.256	< 0.001
HAQ-DI	1765	0.215	< 0.001
DAPSA	949	0.380	< 0.001
Modified MDA (total score)*	1583	-0.291	< 0.001
Patient-reported pain	1754	0.209	< 0.001
Patient-reported fatigue	1865	0.172	< 0.001
Patient global assessment	1880	0.270	< 0.001
BSA	1796	0.027	0.247
EQ5D	1755	-0.186	< 0.001
WPAI			
% Work time missed	957	0.119	< 0.001
% Impairment while working	1011	0.176	< 0.001
% Overall work impairment	892	0.189	< 0.001
% Activity impairment	1652	0.222	< 0.001

* This variable is the total score of the 6 criteria for modified MDA: tender joint count ≤ 1 , swollen joint count ≤ 1 , BSA $\leq 3\%$, patient pain VAS ≤ 15 , patient global assessment VAS ≤ 20 , and HAQ-DI ≤ 0.5 . BSA: body surface area; CDAI: Clinical Disease Activity Index; DAPSA: Disease Activity Index for Psoriatic Arthritis; EQ-5D: Euroqol 5-dimension scale; HAQ-DI: Health Assessment Questionnaire Disability Index; MDA: modified minimal disease activity (defined as meeting ≥ 5 of the following criteria: tender joint count ≤ 1 , swollen joint count ≤ 1 , BSA $\leq 3\%$, patient pain VAS ≤ 15 , patient global assessment VAS ≤ 20 , and HAQ-DI ≤ 0.5); QOL: quality of

Online supplement to: Disease Characteristics, Quality of Life, and Work Productivity by Enthesitis Site: Real-World Data From the US Corona Psoriatic Arthritis/Spondyloarthritis Registry. *The Journal of Rheumatology*. doi:10.3899/jrheum.191117

life; SPARCC: Spondyloarthritis Research Consortium of Canada; VAS: visual analog scale;

WPAI: Work Productivity and Activity Impairment.